News
ROIV
36.16
+2.58%
0.91
Roivant Sciences Price Target Raised to $46.00/Share From $42.00 by Citigroup
Dow Jones · 2d ago
Roivant Sciences Is Maintained at Buy by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Benzinga · 2d ago
Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
TipRanks · 2d ago
Roivant Sciences price target raised to $37 from $35 at BofA
TipRanks · 2d ago
Citi Reaffirms Their Buy Rating on Roivant Sciences (ROIV)
TipRanks · 2d ago
Roivant Sciences price target raised to $46 from $42 at Citi
TipRanks · 2d ago
Weekly Report: what happened at ROIV last week (0803-0807)?
Weekly Report · 2d ago
Bank of America Securities Remains a Hold on Roivant Sciences (ROIV)
TipRanks · 2d ago
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue
Simply Wall St · 3d ago
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Seeking Alpha · 4d ago
Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist
Simply Wall St · 4d ago
Roivant Sciences Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Roivant Sciences Price Target Raised to $42.00/Share From $36.00 by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42
Benzinga · 5d ago
Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)
TipRanks · 5d ago
Roivant Sciences Price Target Raised to $41.00/Share From $34.00 by HC Wainwright & Co.
Dow Jones · 5d ago
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41
Benzinga · 5d ago
TD Cowen boosts Roivant Sciences price target, says has many catalysts on deck
TipRanks · 6d ago
More
Webull provides a variety of real-time ROIV stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.